Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA10 SIROLIMUS COMPR. FILM. 1 mg
RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.
________________________________________________________________________________
______________________________________________________________________________
| 989 |L04AX01| AZATHIOPRINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg
IMURAN(R) 50 mg THE WELLCOME FOUNDATION
LTD.
________________________________________________________________________________
______________________________________________________________________________
| 990 |M05BA04| ACIDUM ALENDRONICUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
M05BA04 ACIDUM ALENDRONICUM COMPR. 10 mg
FOSAMAX 10 mg 10 mg MERCK SHARP & DOHME S.R.L.
M05BA04 ACIDUM ALENDRONICUM COMPR. 70 mg
TEVA NAT 70 mg TEVA PHARMACEUTICALS SRL
M05BA04 ACIDUM ALENDRONICUM COMPR. 70 mg
FOSAMAX 70 mg 70 mg MERCK SHARP & DOHME S.R.L.
________________________________________________________________________________
______________________________________________________________________________
| 991 |N02AB02| PETHIDINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
N02AB02 PETHIDINUM SOL. INJ. 50 mg/ml
MIALGIN(R) 100 mg/2 ml 50 mg/ml ZENTIVA SA
________________________________________________________________________________
______________________________________________________________________________
| 993 |B01AB08| REVIPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB08 REVIPARINUM SOL. INJ.
CLIVARIN (R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ.
CLIVARIN (R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
________________________________________________________________________________
______________________________________________________________________________
| 994 |B05AA06| POLYGELINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B05AA06 POLYGELINUM SOL. PERF. 3.5%
HAEMACCEL 3.5% THERASELECT GMBH
________________________________________________________________________________
______________________________________________________________________________
| 995 |J01XX08| LINEZOLIDUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA
ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEI
ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF.
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEI
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM COMPR. FILM.
ZYVOXID(R) 600 mg PFIZER EUROPE MA EEI
ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 996 |J02AC03| VORICONAZOLUM** | Protocol: J012B |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J02AC03 VORICONAZOLUM COMPR. FILM.
VFEND(R) 200 mg PFIZER LIMITED
VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SOL. PERF.
VFEND(R) 200 mg PFIZER LIMITED
VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALA
VFEND(R) 40 mg/ml 40 mg/ml PFIZER LIMITED
VFEND 40 mg/ml 40 mg/ml PFIZER LTD.
J02AC03 VORICONAZOLUM COMPR. FILM.
VFEND(R) 50 mg PFIZER LIMITED
VFEND 50 mg 50 mg PFIZER LTD.
________________________________________________________________________________
______________________________________________________________________________
| 998 |J05AB14| VALGANCICLOVIRUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul de iniţiere şi menţinere pentru retinita cu citomegalovirus (CMV) la pacienţi imunocompromişi.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg
VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL
J05AB14 VALGANCICLOVIRUM COMPR. FILM.
VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL
________________________________________________________________________________
SUBLISTA C2-P9: PROGRAM NAŢIONAL DE TRANSPLANT DE ORGANE, ŢESUTURI ŞI CELULE DE ORIGINE UMANĂ. P9.6 TRANSPLANT PULMONAR
______________________________________________________________________________
| 999 |B01AB05| ENOXAPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui
anti-Xa/0.8 ml
CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS
anti-Xa/0.8 ml
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
________________________________________________________________________________
______________________________________________________________________________
| 1000 |B01AB08| REVIPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml
CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
________________________________________________________________________________
______________________________________________________________________________
| 1002 |C01CA24| EPINEPHRINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
C01CA24 EPINEPHRINUM SOL. INJ. 1 mg/ml
ADRENALINA 1 mg 1 mg/ml TERAPIA SA
________________________________________________________________________________
______________________________________________________________________________
| 1003 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.
TAZOBACTAMUM
TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH
TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 1004 |J01XX08| LINEZOLIDUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml
ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg
ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 1005 |J02AC01| FLUCONAZOLUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratament de întreţinere la pacienţi cu meningită
Dostları ilə paylaş: |